Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Altimmune

Drug Profile

Coronavirus vaccine - Altimmune

Alternative Names: AdCOVID; COVID-19 vaccine - Altimmune; Intranasal COVID-19 vaccine - Altimmune

Latest Information Update: 19 May 2020

At a glance

  • Originator Altimmune
  • Developer Altimmune; University of Alabama at Birmingham
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 13 May 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Intranasal) before May 2019
  • 13 May 2020 Altimmune plans a phase I trial for COVID-2019 infections (Prevention) (Intranasal) in the fourth quarter of 2020
  • 30 Mar 2020 Altimmune and University of Alabama at Birmingham signs research and development agreement for coronavirus vaccine

Development Overview

Introduction

A coronavirus vaccine (COVID 19) is being developed by Altimmune for prevention against COVID-2019 infections. Altimmune is using its proprietary RespirVec platform to develop the COVID 19 candidate. The vaccine is designed to provide systemic immunity following a single intranasal dose. The intranasal delivery directs the immune response to the site of initial viral attack and provides systemic protection. Preclinical trial is underway in the US.

The RespirVec platform is comprised of intranasal delivery of replication-deficient adenoviruses. The adenovectored pathogen sequences elicits a rapid as well as long-term immune protection. The technology, includes intracellular expression of the vaccine antigen for authentic immune presentation, mobilisation of the innate, cellular and mucosal immune systems instead of just the antibody-based response triggered by conventional injectable vaccines, a more durable antibody response, self-adjuvanting adenovector delivery system with the potential to improve immunogenicity.

Altimmune is actively seeking partners for the development of intranasal coronavirus vaccine (Altimmune pipeline, March 2020).

Company Agreements

In March 2020, Altimmune entered into an agreement with University of Alabama at Birmingham (UAB) for the development of intranasal COVID-19 vaccine, AdCOVID. Under the terms of agreement, initially Altimmune will work with UAB investigators to perform preclinical studies and to analyse the vaccine immunogenicity. [1]

Key Development Milestones

As of May 2020, Altimmune in collaboration with the University of Alabama at Birmingham (UAB) initiated preclinical testing of COVID-19 vaccine [2]

As of February 2020, the design and synthesis of the vaccine was completed. Altimmune announced its intention to advance it towards animal testing and manufacturing [3] .

Drug Properties & Chemical Synopsis

  • Route of administration Intranasal
  • Formulation unspecified
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical USA Intranasal / unspecified Altimmune, University of Alabama at Birmingham 13 May 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Altimmune Originator USA
Altimmune Owner USA
University of Alabama at Birmingham Collaborator USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Altimmune - Unspecified - 05 Mar 2020

Brand Names

Brand Name Organisations Indications Countries
AdCOVID Altimmune COVID 2019 infections USA

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Trial Update Altimmune plans a phase I trial for COVID-2019 infections (Prevention) (Intranasal) in the fourth quarter of 2020 (700320289) [2] 19 May 2020
30 Jun 2020 Trial Update Altimmune plans preclinical studies in the second quarter of 2020 [4] 03 Apr 2020

Development History

Event Date Update Type Comment
13 May 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in USA (Intranasal) before May 2019 [2] Updated 19 May 2020
13 May 2020 Trial Update Altimmune plans a phase I trial for COVID-2019 infections (Prevention) (Intranasal) in the fourth quarter of 2020 [2] Updated 19 May 2020
30 Mar 2020 Licensing Status Altimmune and University of Alabama at Birmingham signs research and development agreement for coronavirus vaccine [1] Updated 06 Apr 2020
27 Mar 2020 Trial Update Altimmune plans preclinical studies in the second quarter of 2020 [4] Updated 03 Apr 2020
05 Mar 2020 Licensing Status Coronavirus vaccine - is available for licensing as of 05 Mar 2020. https://altimmune.com/about-us/ Updated 06 Mar 2020
05 Mar 2020 Trial Update Altimmune plans preclinical studies for COVID-2019 infections (Prevention) [3] Updated 06 Mar 2020
28 Feb 2020 Phase Change Early research in COVID-2019 infections (Prevention) in USA (Intranasal) [3] Updated 06 Mar 2020

References

  1. Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine.

    Media Release
  2. Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update.

    Media Release
  3. Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine.

    Media Release
  4. Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update.

    Media Release
Back to top